SavedAdd your journal

Journals / Bağcılar Tıp Bülteni / 2021 / Cilt: 6 - Sayı: 3

Differentiation of Benign and Malignant Kidney Masses via Inflammation Parameters

Benign ve Malign Böbrek Kitlelerinin Enflamasyon Markerlarıyla Ayrımı

Recep ERYILMAZ
Kasım ERTAŞ
Rahmi ASLAN
Kerem TAKEN
Murat DEMİR
Pages
276–279
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Hematological inflammatory markers are useful in predicting the pathology outcome of kidney masses before surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Despite the recent advances in imaging methods, the rate of 10-20% is still insufficient in predicting the pathology of renal masses.
📊
Key Findings & Data:Method: One hundred sixteen patients who were operated for kidney mass between January 2010 and October 2020 were included in the study.
💡
Conclusion & Impact:Conclusion: Hematological inflammatory markers are useful in predicting the pathology outcome of kidney masses before surgery.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Despite the recent advances in imaging methods, the rate of 10-20% is still insufficient in predicting the pathology of renal masses. Therefore, we aimed to examine whether hematological inflammatory markers were useful in predicting pathology outcome. Method: One hundred sixteen patients who were operated for kidney mass between January 2010 and October 2020 were included in the study. Retrospectively, preoperative platelets, neutrophils, lymphocytes and their rates were compared with pathology results. Results: The mean age of 116 patients included in the study was 55.36±13.93 years. While pathology results of 26 (22.4%) patients were benign, results of 90 (77.6%) patients were malignant. The neutrophil and neutrophil lymphocyte ratio were significantly lower in the benign group. According to the Fuhrman grade of renal cell carcinoma, platelet and platelet lymphocyte ratio were higher in aggressive groups, whereas lymphocyte count was lower. Conclusion: Hematological inflammatory markers are useful in predicting the pathology outcome of kidney masses before surgery.

Özet

Amaç: Görüntüleme yöntemlerindeki son gelişmelere rağmen, böbrek kitlelerinin patolojisini tahmin etmede hala %10-20 oranı yetersizdir. Bu nedenle, hematolojik enflamatuvar belirteçlerin patoloji sonucunu tahmin etmede yararlı olup olmadığını incelemeyi amaçladık. Yöntem: Ocak 2010 ile Ekim 2020 tarihleri arasında böbrek kitlesi nedeniyle opere edilen 116 hasta çalışmaya dahil edildi. Retrospektif olarak preoperatif trombosit, nötrofiller, lenfosit sayıları ve oranları patoloji sonuçları ile karşılaştırıldı. Bulgular: Çalışmaya alınan 116 hastanın yaş ortalaması 55,36±13,93 yıl idi. Yirmi altı (%22,4) hastanın patoloji sonuçları benign iken 90’ı (%77,6) malign idi. Nötrofil sayısı ve nötrofil lenfosit oranı benign grupta anlamlı olarak daha düşüktü. Renal hücreli karsinomlu hastalarda yüksek Fuhrman derecelerinde trombosit sayısı ve trombosit lenfosit oranı daha yüksek iken lenfosit sayısı ise daha düşüktü. Sonuç: Hematolojik enflamatuvar belirteçler, ameliyattan öncesi böbrek kitlelerinin patoloji sonucunu tahmin etmede yararlıdır

🔖

Cite This Article

ERYILMAZ, R., ERTAŞ, K., ASLAN, R., TAKEN, K., DEMİR, M. (2022). Differentiation of Benign and Malignant Kidney Masses via Inflammation Parameters. Bağcılar Tıp Bülteni, Cilt: 6 - Sayı: 3, 276–279. https://ajindex.com/articles/458901

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Li W, Cheng Y, Cheng Y, Ren H, Han N. Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma. Eur J Med Res 2014;19(1):1-6
  2. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 2002;7(4):135-140
  3. Şahin H, Akarken İ. Böbrek Tümörlerinde Etiyoloji, Klinik Tanı ve Evrelemesi. Turk Klin Urol 2019;12(4):1-9
  4. King SC, Pollack LA, Li J, King JB, Master VA. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol 2014;191(6):1665-1670
  5. Morra MN, Das S. Renal oncocytoma: a review of histogenesis, histopathology, diagnosis and treatment. J Urol 1993;150(2 Pt 1):295-302
  6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-899
  7. Yildirim M, Kılınç Y, Ceyhan A. Behçet hastalığı patogenezindeki yenilikler. Suleyman Demirel Univ Tıp Fak Derg 2009;16(3):29-34
  8. Waldner MJ, Neurath MF. Colitis-Associated Cancer: the role of t cells in tumor development. Semin Immunol 2009;31(2):249-256
  9. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431-436
  10. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of t helper type 17 t cell responses. Nat Med 2009;15(9):1016-1022
  11. Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep 2019;9(1):1-10
  12. Duran İ, Avcı V, Nazik S, Altun E. Çocukluk çağı apandisit tanısında nötrofil lenfosit oranı ve trombosit lenfosit oranı. Turk Klin Biyokim Derg 2017;15(1):1-7
  13. Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Cancer Biomark 2015;15(3):317-323
  14. Karaoğullarından Ü, Akkız H, Kuran S, Uskudar O, Taskaynatan H, Delik A. The relationship between thrombocyte lymphocyte ratio with tumor morphology and alpha fetoprotein in patients with hepatocellular carcinoma. Turk J Fam Med and Primary Care 2020;14(2):230-235
  15. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013;109(2):401-407
  16. Kusumanto YH, Dam WA,